{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T12:38:08Z","timestamp":1789562288174,"version":"build-2803163510"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T00:00:00Z","timestamp":1664496000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T00:00:00Z","timestamp":1664496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s10620-022-07704-4","type":"journal-article","created":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T15:02:45Z","timestamp":1664550165000},"page":"1559-1573","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Efficacy and Safety of Bezafibrate Alone or in Combination with Ursodeoxycholic Acid in Primary Biliary Cholangitis: Systematic Review and Meta-Analysis"],"prefix":"10.1007","volume":"68","author":[{"given":"Nidah Shabbir","family":"Khakoo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahnaz","family":"Sultan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5498-6037","authenticated-orcid":false,"given":"Cynthia","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,30]]},"reference":[{"key":"7704_CR1","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1002\/hep.29717","volume":"67","author":"CF Murillo Perez","year":"2018","unstructured":"Murillo Perez CF, Goet JC, Lammers WJ et al. Milder disease stage in patients with primary biliary cholangitis over a 44-year period: a changing natural history. Hepatology 2018;67:1920\u20131930. https:\/\/doi.org\/10.1002\/hep.29717.","journal-title":"Hepatology"},{"key":"7704_CR2","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.cld.2018.03.007","volume":"22","author":"A Goel","year":"2018","unstructured":"Goel A, Kim WR. Natural history of primary biliary cholangitis in the ursodeoxycholic acid era: role of scoring systems. Clin Liver Dis 2018;22:563\u2013578. https:\/\/doi.org\/10.1016\/j.cld.2018.03.007.","journal-title":"Clin Liver Dis"},{"key":"7704_CR3","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1055\/s-0034-1383731","volume":"34","author":"MH Imam","year":"2014","unstructured":"Imam MH, Lindor KD. The natural history of primary biliary cirrhosis. Semin Liver Dis 2014;34:329\u2013333. https:\/\/doi.org\/10.1055\/s-0034-1383731.","journal-title":"Semin Liver Dis"},{"key":"7704_CR4","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1056\/NEJMoa1714519","volume":"378","author":"C Corpechot","year":"2018","unstructured":"Corpechot C, Chazouilleres O, Rousseau A et al. A placebo-controlled trial of bezafibrate in primary biliary cholangitis. N Engl J Med 2018;378:2171\u20132181. https:\/\/doi.org\/10.1056\/NEJMoa1714519.","journal-title":"N Engl J Med"},{"key":"7704_CR5","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1097\/MCG.0b013e3181c115b3","volume":"44","author":"R Hazzan","year":"2010","unstructured":"Hazzan R, Tur-Kaspa R. Bezafibrate treatment of primary biliary cirrhosis following incomplete response to ursodeoxycholic acid. J Clin Gastroenterol 2010;44:371\u2013373. https:\/\/doi.org\/10.1097\/MCG.0b013e3181c115b3.","journal-title":"J Clin Gastroenterol"},{"key":"7704_CR6","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1002\/hep.30145","volume":"69","author":"KD Lindor","year":"2019","unstructured":"Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases. Hepatology 2019;69:394\u2013419. https:\/\/doi.org\/10.1002\/hep.30145.","journal-title":"Hepatology"},{"key":"7704_CR7","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1053\/j.gastro.2014.08.029","volume":"147","author":"WJ Lammers","year":"2014","unstructured":"Lammers WJ, Van Buuren HR, Hirschfield GM et al. Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. Gastroenterology 2014;147:1338-1349.e5. https:\/\/doi.org\/10.1053\/j.gastro.2014.08.029.","journal-title":"Gastroenterology"},{"key":"7704_CR8","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","volume":"130","author":"A Par\u00e9s","year":"2006","unstructured":"Par\u00e9s A, Caballer\u00eda L, Rod\u00e9s J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology 2006;130:715\u2013720. https:\/\/doi.org\/10.1053\/j.gastro.2005.12.029.","journal-title":"Gastroenterology"},{"key":"7704_CR9","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1080\/14656566.2021.1940135","volume":"22","author":"A Wetten","year":"2021","unstructured":"Wetten A, Jones DEJ, Dyson JK. Specific considerations for the management of primary biliary cholangitis: are the drug treatment options good enough? Expert Opin Pharmacother 2021;22:1949\u20131953. https:\/\/doi.org\/10.1080\/14656566.2021.1940135.","journal-title":"Expert Opin Pharmacother"},{"key":"7704_CR10","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1002\/hep.26018","volume":"57","author":"A Honda","year":"2013","unstructured":"Honda A, Ikegami T, Nakamuta M et al. Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid. Hepatology 2013;57:1931\u20131941. https:\/\/doi.org\/10.1002\/hep.26018.","journal-title":"Hepatology"},{"key":"7704_CR11","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/ajg.2017.287","volume":"113","author":"A Reig","year":"2018","unstructured":"Reig A, Ses\u00e9 P, Par\u00e9s A. Effects of bezafibrate on outcome and pruritus in primary biliary cholangitis with suboptimal ursodeoxycholic acid response. Am J Gastroenterol 2018;113:49\u201355. https:\/\/doi.org\/10.1038\/ajg.2017.287.","journal-title":"Am J Gastroenterol"},{"key":"7704_CR12","doi-asserted-by":"publisher","first-page":"5407","DOI":"10.2147\/DDDT.S92041","volume":"9","author":"Q Yin","year":"2015","unstructured":"Yin Q, Li J, Xia Y et al. Systematic review and meta-analysis: Bezafibrate in patients with primary biliary cirrhosis. Drug Des Devel Ther 2015;9:5407\u20135419. https:\/\/doi.org\/10.2147\/DDDT.S92041.","journal-title":"Drug Des Devel Ther"},{"key":"7704_CR13","doi-asserted-by":"publisher","first-page":"489","DOI":"10.20524\/aog.2019.0403","volume":"32","author":"R Agrawal","year":"2019","unstructured":"Agrawal R, Majeed M, Attar BM et al. Effectiveness of bezafibrate and ursodeoxycholic acid in patientwith primary biliary cholangitis: a meta-analysis of randomized controlled trials. Ann Gastroenterol 2019;32:489\u2013497. https:\/\/doi.org\/10.20524\/aog.2019.0403.","journal-title":"Ann Gastroenterol"},{"key":"7704_CR14","unstructured":"Chou R, Aronson N, Atkins D, Ismaila A, Santaguida P. Methods reference guide for effectiveness and comparative effectiveness reviews assessing harms when comparing medical interventions. Agency Healthc Res Qual. 2008."},{"key":"7704_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n160","author":"M Page","year":"2021","unstructured":"Page M, Moher D, Bossuyt P. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021. https:\/\/doi.org\/10.1136\/bmj.n160.","journal-title":"BMJ"},{"key":"7704_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-020-01542-z","author":"M Rethlefsen","year":"2021","unstructured":"Rethlefsen M, Kirtley S, Waffenschmidt S. PRISMA-S: an extension to the PRISMA statement for reporting literature searches in systematic reviews. Syst Rev. 2021. https:\/\/doi.org\/10.1186\/s13643-020-01542-z.","journal-title":"Syst Rev"},{"key":"7704_CR17","unstructured":"Lefebvre CG, Briscoe S, Littlewood A, et al. Chapter 4: Searching for and selecting studies in Cochrane Handbook for Systematic Reviews of Interventions. In: Version 6.0."},{"key":"7704_CR18","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1111\/hir.12269","volume":"36","author":"J Glanville","year":"2019","unstructured":"Glanville J, Foxlee R, Wisniewski S, Noel-Storr A, Edwards M, Dooley G. Translating the Cochrane EMBASE RCT filter from the Ovid interface to Embase.com: a case study. Heal Info Libr J 2019;36:264\u2013277.","journal-title":"Heal Info Libr J"},{"key":"7704_CR19","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/j.jclinepi.2006.03.004","volume":"59","author":"A Furlan","year":"2006","unstructured":"Furlan A, Irvin E, Bombardier C. Limited search strategies were effective in finding relevant nonrandomized studies. J Clin Epidemiol 2006;59:1303\u20131311.","journal-title":"J Clin Epidemiol"},{"key":"7704_CR20","unstructured":"Scottish Intercollegiate Guidelines Network (SIGN). Search Filters: Observational Studies."},{"key":"7704_CR21","unstructured":"Endnote X8. 2013."},{"key":"7704_CR22","unstructured":"Covidence Systematic Review Software."},{"key":"7704_CR23","unstructured":"Rohatgi A. WebPlotDigitizer Version 4.3. 2020."},{"key":"7704_CR24","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JPT Higgins","year":"2011","unstructured":"Higgins JPT, Altman DG, G\u00f8tzsche PC et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928\u2013d5928. https:\/\/doi.org\/10.1136\/bmj.d5928.","journal-title":"BMJ"},{"key":"7704_CR25","unstructured":"Sch\u00fcnemann H, Bro\u017cek J, Guyatt G, Oxman A. GRADE Handbook."},{"key":"7704_CR26","unstructured":"Sch\u00fcnemann HJ. GRADEpro. [Computer Program]."},{"key":"7704_CR27","unstructured":"Review Manager (RevMan) [Computer Program]. The Nordic Cochrane Center, The Cochrane Collaboration."},{"key":"7704_CR28","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/1468-2389.00156","volume":"8","author":"JE Hunter","year":"2000","unstructured":"Hunter JE, Schmidt FL. Fixed effects vs. random effects meta-analysis models: implications for cumulative research knowledge. Int J Sel Assess 2000;8:275\u2013292. https:\/\/doi.org\/10.1111\/1468-2389.00156.","journal-title":"Int J Sel Assess"},{"key":"7704_CR29","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jclinepi.2017.05.005","volume":"87","author":"GH Guyatt","year":"2017","unstructured":"Guyatt GH, Ebrahim S, Alonso-Coello P et al. GRADE guidelines 17: assessing the risk of bias associated with missing participant outcome data in a body of evidence. J Clin Epidemiol 2017;87:14\u201322. https:\/\/doi.org\/10.1016\/j.jclinepi.2017.05.005.","journal-title":"J Clin Epidemiol"},{"key":"7704_CR30","doi-asserted-by":"crossref","unstructured":"Higgins J, Lasserson T, Chandler J, et al. Methodological Expectations of Cochrane Intervention Reviews. 6.1. The Cochrane Collaboration; 2021.","DOI":"10.1002\/9781119536604.ch1"},{"key":"7704_CR31","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"7704_CR32","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/ajg.2015.20","volume":"110","author":"K Hosonuma","year":"2015","unstructured":"Hosonuma K, Sato K, Yamazaki Y et al. A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia. Am J Gastroenterol 2015;110:423\u2013431. https:\/\/doi.org\/10.1038\/ajg.2015.20.","journal-title":"Am J Gastroenterol"},{"key":"7704_CR33","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.hepres.2004.04.001","volume":"29","author":"J Itakura","year":"2004","unstructured":"Itakura J, Izumi N, Nishimura Y et al. Prospective randomized crossover trial of combination therapy with bezafibrate and UDCA for primary biliary cirrhosis. Hepatol Res 2004;29:216\u2013222. https:\/\/doi.org\/10.1016\/j.hepres.2004.04.001.","journal-title":"Hepatol Res"},{"key":"7704_CR34","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1111\/j.1872-034X.2007.00305.x","volume":"38","author":"S Iwasaki","year":"2008","unstructured":"Iwasaki S, Ohira H, Nishiguchi S et al. The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: a prospective, multicenter study. Hepatol Res 2008;38:557\u2013564. https:\/\/doi.org\/10.1111\/j.1872-034X.2007.00305.x.","journal-title":"Hepatol Res"},{"key":"7704_CR35","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s00535-002-1102-7","volume":"38","author":"T Kanda","year":"2003","unstructured":"Kanda T, Yokosuka O, Imazeki F, Saisho H. Bezafibrate treatment: a new medical approach for PBC patients? J Gastroenterol 2003;38:573\u2013578. https:\/\/doi.org\/10.1007\/s00535-002-1102-7.","journal-title":"J Gastroenterol"},{"key":"7704_CR36","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1111\/j.1572-0241.2000.01667.x","volume":"95","author":"S Nakai","year":"2000","unstructured":"Nakai S, Masaki T, Kurokohchi K, Deguchi A, Nishioka M. Combination therapy of bezafibrate and ursodeoxycholic acid in primary biliary cirrhosis: a preliminary study. Am J Gastroenterol 2000;95:326\u2013327. https:\/\/doi.org\/10.1111\/j.1572-0241.2000.01667.x.","journal-title":"Am J Gastroenterol"},{"key":"7704_CR37","doi-asserted-by":"publisher","first-page":"2990","DOI":"10.1111\/j.1572-0241.2000.03220.x","volume":"95","author":"T Kurihara","year":"2000","unstructured":"Kurihara T, Niimi A, Maeda A, Shigemoto M, Yamashita K. Bezafibrate in the treatment of primary biliary cirrhosis: comparison with ursodeoxycholic acid. Am J Gastroenterol 2000;95:2990\u20132992. https:\/\/doi.org\/10.1111\/j.1572-0241.2000.03220.x.","journal-title":"Am J Gastroenterol"},{"key":"7704_CR38","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1111\/j.1440-1746.2011.06737.x","volume":"26","author":"Y Takeuchi","year":"2011","unstructured":"Takeuchi Y, Ikeda F, Fujioka S et al. Additive improvement induced by bezafibrate in patients with primary biliary cirrhosis showing refractory response to ursodeoxycholic acid. J Gastroenterol Hepatol 2011;26:1395\u20131401. https:\/\/doi.org\/10.1111\/j.1440-1746.2011.06737.x.","journal-title":"J Gastroenterol Hepatol"},{"key":"7704_CR39","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/S1386-6346(99)00033-9","volume":"16","author":"S Iwasaki","year":"1999","unstructured":"Iwasaki S, Tsuda K, Ueta H et al. Bezafibrate may have a beneficial effect in pre-cirrhotic primary biliary cirrhosis. Hepatol Res 1999;16:12\u201318. https:\/\/doi.org\/10.1016\/S1386-6346(99)00033-9.","journal-title":"Hepatol Res"},{"key":"7704_CR40","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1034\/j.1600-0676.2001.021003223.x","volume":"21","author":"K Ohmoto","year":"2001","unstructured":"Ohmoto K, Mitsui Y, Yamamoto S. Letter to the Editor Effect of bezafibrate in primary biliary cirrhosis\u202f: a pilot study. Liver 2001;21:223\u2013224.","journal-title":"Liver"},{"key":"7704_CR41","unstructured":"Weber-Freissmuth C, Kozbial K, Staettermayer A, Beinhardt S. Effect of fibrate-add-on treatment in primary biliary cholangitis patients with an insufficient response to ursodeoxycholic acid (UDCA)."},{"key":"7704_CR42","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1007\/s00535-006-1831-0","volume":"41","author":"R Kita","year":"2006","unstructured":"Kita R, Takamatsu S, Kimura T, Kokuryu H, Osaki Y, Tomono N. Bezafibrate may attenuate biliary damage associated with chronic liver diseases accompanied by high serum biliary enzyme levels. J Gastroenterol 2006;41:686\u2013692. https:\/\/doi.org\/10.1007\/s00535-006-1831-0.","journal-title":"J Gastroenterol"},{"key":"7704_CR43","doi-asserted-by":"publisher","first-page":"304","DOI":"10.3760\/cma.j.issn.1007-3418.2019.04.012","volume":"27","author":"BL Feng","year":"2019","unstructured":"Feng BL, Yu HH, Shen W. Ursodeoxycholic acid combined with bezafibrate in the treatment of refractory primary biliary cholangitis: a meta-analysis. Chin J Hepatol 2019;27:304\u2013311. https:\/\/doi.org\/10.3760\/cma.j.issn.1007-3418.2019.04.012.","journal-title":"Chin J Hepatol"},{"key":"7704_CR44","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-004720","author":"F Peinemann","year":"2014","unstructured":"Peinemann F, Labeit AM, Thielscher C, Pinkawa M. Failure to address potential bias in non-randomised controlled clinical trials may cause lack of evidence on patientreported outcomes: a method study. BMJ Open. 2014. https:\/\/doi.org\/10.1136\/bmjopen-2013-004720.","journal-title":"BMJ Open"},{"key":"7704_CR45","doi-asserted-by":"publisher","first-page":"e609","DOI":"10.1097\/MD.0000000000000609","volume":"94","author":"GQ Zhu","year":"2015","unstructured":"Zhu GQ, Shi KQ, Huang S et al. Network meta-analysis of randomized controlled trials: Efficacy and safety of UDCA-based therapies in primary biliary cirrhosis. Med (United States) 2015;94:e609. https:\/\/doi.org\/10.1097\/MD.0000000000000609.","journal-title":"Med (United States)"},{"key":"7704_CR46","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/dmrr.2353","volume":"28","author":"A Ramachandran","year":"2012","unstructured":"Ramachandran A, Chamukuttan S, Shetty SA, Arun N, Susairaj P. Obesity in Asia\u2014is it different from rest of the world. Diabetes Metab Res Rev 2012;28:47\u201351. https:\/\/doi.org\/10.1002\/dmrr.2353.","journal-title":"Diabetes Metab Res Rev"},{"key":"7704_CR47","doi-asserted-by":"publisher","first-page":"3596","DOI":"10.1007\/s10620-017-4812-7","volume":"62","author":"J Ahmad","year":"2017","unstructured":"Ahmad J, Odin JA, Hayashi PH et al. Identification and characterization of fenofibrate-induced liver injury. Dig Dis Sci 2017;62:3596\u20133604. https:\/\/doi.org\/10.1007\/s10620-017-4812-7.","journal-title":"Dig Dis Sci"},{"key":"7704_CR48","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1111\/liv.14871","volume":"41","author":"AF Carrion","year":"2021","unstructured":"Carrion AF, Lindor KD, Levy C. Safety of fibrates in cholestatic liver diseases. Liver Int 2021;41:1335\u20131343. https:\/\/doi.org\/10.1111\/liv.14871.","journal-title":"Liver Int"},{"key":"7704_CR49","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1002\/hep.30552","volume":"70","author":"A Honda","year":"2019","unstructured":"Honda A, Tanaka A, Kaneko T et al. Bezafibrate improves GLOBE and UK-PBC scores and long-term outcomes in patients with primary biliary cholangitis. Hepatology 2019;70:2035\u20132046. https:\/\/doi.org\/10.1002\/hep.30552.","journal-title":"Hepatology"},{"key":"7704_CR50","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1111\/apt.13519","volume":"43","author":"AC Cheung","year":"2016","unstructured":"Cheung AC, Kowgier M, Feld JJ. Editorial: fenofibrate as second-line therapy in high risk PBC\u2013more answers or more questions? Authors\u2019 reply. Aliment Pharmacol Ther 2016;43:649\u2013650. https:\/\/doi.org\/10.1111\/apt.13519.","journal-title":"Aliment Pharmacol Ther"},{"key":"7704_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.04.010","author":"A Tanaka","year":"2021","unstructured":"Tanaka A, Hirohara J, Nakano T et al. Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis. J Hepatol. 2021. https:\/\/doi.org\/10.1016\/j.jhep.2021.04.010.","journal-title":"J Hepatol"},{"key":"7704_CR52","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1002\/hep.30941","volume":"70","author":"E Culver","year":"2019","unstructured":"Culver E, Hayden J, Thorburn D et al. S1271: obeticholic acid and bezafibrate in primary biliary cholangitis: a comparative evaluation of efficacy through real world clinical practice. Hepatology 2019;70:188\u20131382. https:\/\/doi.org\/10.1002\/hep.30941.","journal-title":"Hepatology"},{"key":"7704_CR53","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1111\/apt.16618","volume":"54","author":"JA Sorda","year":"2021","unstructured":"Sorda JA, Gonz\u00e1lez Ballerga E, Barreyro FJ et al. Bezafibrate therapy in primary biliary cholangitis refractory to ursodeoxycholic acid: a longitudinal study of paired liver biopsies at 5 years of follow up. Aliment Pharmacol Ther 2021;54:1202\u20131212. https:\/\/doi.org\/10.1111\/apt.16618.","journal-title":"Aliment Pharmacol Ther"},{"key":"7704_CR54","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s00535-020-01664-0","volume":"55","author":"DMH Chascsa","year":"2020","unstructured":"Chascsa DMH, Lindor KD. Emerging therapies for PBC. J Gastroenterol 2020;55:261\u2013272. https:\/\/doi.org\/10.1007\/s00535-020-01664-0.","journal-title":"J Gastroenterol"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-022-07704-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-022-07704-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-022-07704-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T03:34:21Z","timestamp":1681356861000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-022-07704-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,30]]},"references-count":54,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["7704"],"URL":"https:\/\/doi.org\/10.1007\/s10620-022-07704-4","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,30]]},"assertion":[{"value":"5 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"NSK, SS, JR have no financial conflicts of interest to disclose. CL has research grants from CymaBay, Genfit, Intercept, Zydus, Cara Therapeutics, Mirum, Calliditas, Gilead, GSK and TARGET-RWE. CL has consulting fees from CymaBay, Genfit, Cara Therapeutics, Mirum, Calliditas and GSK.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}